AScurvy (vitamin C deficiency)
First line
First-line treatment for scurvy. Treatment dose is 200 mg daily for 5 days or 1,000 mg daily for 1–2 weeks, then maintenance at the physiological 75–90 mg daily. Symptoms (bleeding gums, petechiae, arthralgia) resolve over 2–4 weeks. BMJ 2018 and BNF support oral treatment; parenteral administration is reserved for severe malabsorption.
CWound healing support
Individual decision
The evidence base is weak and mixed. Supplemental vitamin C 500–1,000 mg daily is considered in patients with nutritional deficiency, after major surgery, with burns, or in older adults with pressure ulcers – only as part of overall nutritional correction. NPUAP/EPUAP 2019 recommend vitamin C as part of nutritional support in pressure ulcers. The 2014 Cochrane review on vitamins and pressure ulcer healing (Langer 2014) is methodologically weak; large RCTs are absent. In patients without confirmed deficiency, isolated vitamin C does not affect wound healing time. The foundational approach is nutritional status assessment and correction of deficiencies as a whole, not mega-dose ascorbic acid.
DCommon cold
Not recommended
The 2013 Cochrane review (29 RCTs, more than 11,000 participants) showed that regular vitamin C 200 mg daily or higher in the general population does not reduce respiratory infection incidence. In athletes under extreme physical stress, the risk drops by 50% with daily intake. In most adults, routine vitamin C for cold prevention has no proven benefit. Symptom duration reduction when started after onset is about 8% in adults – minimal clinical significance.
DExercise-induced bronchoconstriction
Not recommended
The 2014 Cochrane review did not confirm an effect of vitamin C on asthma symptoms or prevention of exercise-induced bronchospasm. International pulmonology societies (GINA) do not include vitamin C in asthma management standards. Small positive RCTs have not been reproduced.
FAnti-aging and longevity (marketed indication)
Not recommended
International guidelines do not support vitamin C for anti-ageing or lifespan extension. The antioxidant theory of ageing, on which «vitamin C against ageing» marketing relies, has not been confirmed in large RCTs. Physicians' Health Study II (14,641 men, 8 years) showed no reduction in all-cause mortality or chronic disease incidence with vitamin C. Doses above 2,000 mg daily increase kidney oxalate stone risk.
FCancer prevention
Not recommended
High-dose vitamin C is not supported by international guidelines as cancer prevention or treatment. The mega-dose concept originates in Linus Pauling's 1970s publications and has not been confirmed in large subsequent RCTs. NCI PDQ summary states clearly: RCTs have not confirmed an effect of high-dose ascorbic acid on cancer outcomes. Intravenous vitamin C drips at doses of 25–75 g offered in private clinics as «cancer treatment» or «prevention» fall outside NCCN, ESMO, and ASCO recommendations. Large meta-analyses (Zhang 2013, Luo 2014) showed no effect on all-cause or cardiovascular mortality. In patients with established cancer, high-dose vitamin C should be discussed with the treating oncologist because it may reduce the efficacy of some cytotoxic agents and radiotherapy.
FChronic fatigue without a clinical diagnosis
Not recommended
Vitamin C «for energy and vitality» provides no clinical benefit in people without documented serum ascorbic acid deficiency. A subjective «energising» feeling from vitamin C has not been reproduced in RCTs. Intravenous vitamin drips in private clinics as «fatigue relief» are a marketing service outside international guidelines. Chronic fatigue requires differential workup: anaemia, hypothyroidism, depression, iron or B12 deficiency – the identified cause is treated, not «boosted» with vitamin C mega-doses.
FPrimary cardiovascular prevention in individuals without established CVD
Not recommended
International guidelines do not include vitamin C for primary cardiovascular prevention in healthy adults. Large RCTs (Physicians' Health Study II 2012, HOPE 2000, HOPE-TOO 2005) on antioxidant vitamins did not confirm effects on myocardial infarction, stroke, or cardiovascular mortality. ESC 2021 and AHA do not include vitamin C in CVD prevention recommendations. The antioxidant hypothesis of vascular protection has not translated clinically, although the effect is reproducible in laboratory models.